MERUS N.V. EO -09 (2GH F) stock market data APIs
€51.6278
0(0%)
as of July 18, 2025
Try our APIs with
free plan!
MERUS N.V. EO -09 Financial Data Overview
Price chart is built with
Anychart
Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes BIZENGRI for the treatment of patients with pancreatic adenocarcinoma or non-small cell lung cancer (NSCLC) and non Neuregulin 1. The company is also developing MCLA-158 for the treatment of solid tumors; MCLA-129 for the treatment of patients with lungs and other solid tumors; ONO-4685 to treat relapsed/refractory T cell lymphoma; and INCA33890 for advanced solid tumors. In addition, it has collaboration agreement with Eli Lilly and Company, Ono Pharmaceutical Co., Ltd., and Betta Pharmaceuticals Co. Ltd. The company was incorporated in 2003 and is headquartered in Utrecht, the Netherlands.
Prev. Close
51.6278
Open
51.6278
High
51.6278
Low
51.6278
52 wk Range
29.4-56.5
Market Cap
3 836 M
Shares Outstanding
74 477 K
Revenue
54 732 K
EPS
-1.4
Beta
1.036
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get MERUS N.V. EO -09 data using free add-ons & libraries
Get MERUS N.V. EO -09 Fundamental Data
MERUS N.V. EO -09 Fundamental data includes:
- Net Revenue: 54 732 K
- EBITDA: -298 552 992
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-07
- EPS/Forecast: 0
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
MERUS N.V. EO -09 News
New
MRUS Stock Soars 30% in 3 Months After Phase II Cancer Study Success
Merus N.V. MRUS shares have jumped 29.9% over the past three months. The uptrend was fueled by encouraging interim results from a phase II study evaluating its bispecific antibody, petosemtamab (MCLA-...
Merus, Bicara Present Promising HNSCC Trial Data at ASCO 2025, Advance Towards Phase III
Merus (NASDAQ:MRUS) is one of the most promising stocks according to Wall Street analysts. The 2025 Annual Meeting of the American Society of Clinical Oncology/ASCO, held in Chicago, the US, from May ...
Why Merus N.V. (MRUS) Crashed On Wednesday
We recently published a list of Investors Are Dumping These 10 Stocks. In this article, we are going to take a look at where Merus N.V. (NASDAQ:MRUS) stands against other worst-performing stocks on W...
Merus N.V. Announces Pricing of Public Offering of Common Shares
Merus N.V. UTRECHT, The Netherlands and CAMBRIDGE, Mass., June 04, 2025 (GLOBE NEWSWIRE) -- Merus N.V. (Nasdaq: MRUS) (“Merus”, the “Company,” “we” and “our”), an oncology company dev...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
